Lucy Navsaria

The University of Texas MD Anderson Cancer Center

Also affiliated with University of California, Irvine

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma”.

Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma

Journal of Clinical Oncology(2021)10.1200/jco.21.01797

N/A

2.5DataRank · unranked

83 citations

Shuangtao Zhao, Hun Ju Lee, Holly A. Hill, Chi Young Ok, Rashmi Kanagal‐Shamanna +22 more

Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00638-0

N/A

1.5DataRank · unranked

56 citations

Preetesh Jain, Shuangtao Zhao, Hun Ju Lee, Loretta J. Nastoupil, Luis Fayad +32 more